BACKGROUND: Multiple studies implicate the renin-angiotensin system in hepatic fibrogenesis. Few studies have examined the effects of angiotensin blockade on liver fibrosis via human histology. AIMS: We studied the histological effect of angiotensin II blocking agents in chronic hepatitis C patients. METHODS: This was a retrospective study of 284 chronic hepatitis C patients from 2001 to 2006 who underwent a liver biopsy. Group I was comprised of 143 hypertensive patients who received angiotensin-blocking agents. Group II was comprised of 91 hypertensive subjects who received hypertensive agents other than angiotensin blockers. Group III was comprised of 50 non-hypertensive subjects. RESULTS: The groups were similar in age, sex, hepatitis C genotype, viral load and disease duration. They varied significantly in total diabetic patients (Group I, 43; Group II, 10; Group III, 1; P=0.0001), consistent with recommended use of angiotensin-converting enzyme inhibitors in hypertensive diabetics. Non-hypertensive patients had significantly less fibrosis than hypertensive patients, regardless of antihypertensive medications (Group I, 3.20; Group II, 3.73; Group III, 2.5; P=0.0002). Group I had significantly less fibrosis than Group II (P=0.02). This finding persisted in a non-diabetic subgroup of Groups I and II (Group I, 3.07; Group II, 3.69; P=0.0129). CONCLUSION: Patients with hepatitis C and hypertension have increased fibrosis compared with non-hypertensive patients. Hypertensive patients receiving angiotensin-blocking agents had less fibrosis than hypertensive patients who did not receive angiotensin-blocking agents. This suggests an association with hypertension, possibly via the renin-angiotensin system in the fibrosis development and suggests a beneficial role of angiotensin II blockade in hepatitis C virus-related fibrosis.
BACKGROUND: Multiple studies implicate the renin-angiotensin system in hepatic fibrogenesis. Few studies have examined the effects of angiotensin blockade on liver fibrosis via human histology. AIMS: We studied the histological effect of angiotensin II blocking agents in chronic hepatitis Cpatients. METHODS: This was a retrospective study of 284 chronic hepatitis Cpatients from 2001 to 2006 who underwent a liver biopsy. Group I was comprised of 143 hypertensivepatients who received angiotensin-blocking agents. Group II was comprised of 91 hypertensive subjects who received hypertensive agents other than angiotensin blockers. Group III was comprised of 50 non-hypertensive subjects. RESULTS: The groups were similar in age, sex, hepatitis C genotype, viral load and disease duration. They varied significantly in total diabeticpatients (Group I, 43; Group II, 10; Group III, 1; P=0.0001), consistent with recommended use of angiotensin-converting enzyme inhibitors in hypertensive diabetics. Non-hypertensivepatients had significantly less fibrosis than hypertensivepatients, regardless of antihypertensive medications (Group I, 3.20; Group II, 3.73; Group III, 2.5; P=0.0002). Group I had significantly less fibrosis than Group II (P=0.02). This finding persisted in a non-diabetic subgroup of Groups I and II (Group I, 3.07; Group II, 3.69; P=0.0129). CONCLUSION:Patients with hepatitis C and hypertension have increased fibrosis compared with non-hypertensivepatients. Hypertensivepatients receiving angiotensin-blocking agents had less fibrosis than hypertensivepatients who did not receive angiotensin-blocking agents. This suggests an association with hypertension, possibly via the renin-angiotensin system in the fibrosis development and suggests a beneficial role of angiotensin II blockade in hepatitis C virus-related fibrosis.
Authors: J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell Journal: Gastroenterology Date: 2001-07 Impact factor: 22.682
Authors: G Paizis; R E Gilbert; M E Cooper; P Murthi; J M Schembri; L L Wu; J R Rumble; D J Kelly; C Tikellis; A Cox; R A Smallwood; P W Angus Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner Journal: Antioxid Redox Signal Date: 2014-01-24 Impact factor: 8.401